Skip to content
Screener

Halozyme Therapeutics HALO Q2 2026 earnings

Reported August 6, 2026 · After market close

Revenue$481.0MBeat by $78.7M
EPS$2.28Beat by $0.49
Revenue estimate$402.3M
EPS estimate$1.79
“We delivered another quarter of strong performance, with multiple proof points demonstrating the attractive features of ENHANZE as a compounding platform engine: repeatability of success, scalability, diversification and durability of revenues. Total revenue increased 48% year-over-year to $481 million, royalty revenue increased 50% to $308 million and adjusted EBITDA grew 46% to $329 million, reflecting the strength of our differentiated royalty business. Based on these record results, we are raising our full year 2026 financial guidance.”
Dr. Helen Torley

Next report

Nov 2, 2026 (in a month)
Revenue estimate$482.3M
EPS estimate$2.25

Financials

Q2 2026

Income statement

See full
Revenue$481.0M+47.7%
Gross profit$401.8M+43.8%
Operating income$287.7M+42.1%
Net income$229.9M+39.2%
EPS (diluted)$1.90+42.9%

Balance sheet

See full
Cash & equivalents$164.0M+165%
Total debt$2.2B+41.6%
Total equity$143.5M-56.9%
Total assets$2.6B+25.5%

Cash flow

See full
Operating cash flow$240.9M+142%
CapEx$4.2M+167%
Free cash flow$236.7M+141%

Valuation & ratios

Valuation

as of 09/17/26
See full
Market cap$12.31B+38.8%
Enterprise value$14.32B+38.5%
P/E17.1×—
P/S7.4×-0.1×

Profitability

See full
Gross margin82.4%-1.8pp
FCF margin48.5%+2.6pp

Returns & leverage

See full
Debt / equity15.2×+10.6×
Current ratio2.7×-5.7×

Segments

By product

See full
Royalties$307.7M+49.6%
Bulk rHuPH20 sales$59.6M+156%
Proprietary product sales$55.4M+19.3%
Upfront license and target nomination fees$35.5M—
Device partnered product sales$14.6M+23.7%

FAQ

When did Halozyme Therapeutics report Q2 2026 earnings?
Halozyme Therapeutics (HALO) reported Q2 2026 earnings on August 6, 2026 after market close.
What were Halozyme Therapeutics's Q2 2026 revenue and EPS?
Halozyme Therapeutics reported revenue of $481.0M and eps of $2.28 for Q2 2026.
Did Halozyme Therapeutics beat estimates in Q2 2026?
Revenue beat the consensus estimate of $402.3M by $78.7M. EPS beat the consensus estimate of $1.79 by $0.49.
How did Halozyme Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 47.7% from $325.7M a year earlier and eps grew 48.1% from $1.54.
Where can I find Halozyme Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001159036-26-000103) and the 10-Q periodic report (0001159036-26-000104) directly on SEC EDGAR. The filing index links above go to sec.gov.